URGENT CALL TO HEALTH AND POLITICAL AUTHORITIES TO RECONSIDER MASS VACCINATION IN THE LIGHT OF RECENT SCIENTIFIC OBSERVATIONS ON SARS-COV-2 AND THE SPIKE PROTEIN.
by Dr. Klaus Schustereder, Dr Philippe Saegesser, Francois Daubé, Irina Penzo, Christian Camus et Rene Schluter
I – Introduction
Recent scientific publications providing an initial assessment of the effect of vaccines have drawn our attention.
These studies date back to 2021 and illuminates some critical actions of the spike protein in the body.
These are not opinions, therefore, but the results of research conducted by several scientific teams.
According to these publications, the Spike protein and its pathophysiological effects on endothelial cells can have grave and diverse pathogenic consequences for certain individuals.
This latest knowledge makes it possible to re-assess the benefit/risk ratio and to draw lessons from it in order to re-adjust the vaccination campaign.
Given that it is inoculated massively and mostly on a healthy population, the introduction of this Spike protein into human cells by injection must accordingly be urgently re-evaluated by taking into account the risks we did not fully understand before.
We therefore appeal to the health and political authorities to pay the greatest attention to these publications, a summary of which is presented below, and the references of which are provided in the appendix.
In the light of the recent studies presented below, we ask for an URGENT REVIEW BY AGE CLASS of the safety and expediency of the Sars-CoV-2 vaccines currently used in Switzerland and Europe.
II – Physiological aspect
SARS-CoV-2 may have effects on the human vascular system, including that of the brain. The primary function of the Spike protein is to allow the entry of the virus into a host cell via binding to the ACE2 receptor located in the cell membrane. ACE2 is a type I integral membrane protein that cleaves angiotensin II in angiotensin I, thus removing angiotensin II and lowering the blood pressure.
In a series of papers, Yuichiro Suzuki in collaboration with other authors presented a strong argument that the Spike protein by itself can cause a signaling response in the vasculature with potentially widespread consequences. (Suzuki, 2020; Suzuki et al., 2020; Suzuki et al., 2021; Suzuki and Gychka, 2021).
These authors observed that, in severe cases of COVID-19, SARS-CoV-2 generates significant morphological changes to the pulmonary vascular system. Postmortem examination of the lungs of patients who died of COVID-19 uncovered histological features showing thickening of the vascular wall, mainly due to hypertrophy of the tunica media. The hypertrophied smooth muscle cells had become rounded, with swollen nuclei and cytoplasmic vacuoles (Suzuki et al., 2020).
In addition, they showed that exposure of cultured human pulmonary artery smooth muscle cells to the SARS-CoV-2 Spike protein S1 subunit was sufficient to promote cell signalling even without the rest of the virus components being present.
Follow-up papers (Suzuki et al., 2021, Suzuki and Gychka, 2021) demonstrated that the Spike protein S1 subunit suppresses ACE2, triggering a condition resembling pulmonary arterial hypertension (PAH), a severe lung disease with very high mortality.
Worryingly, Suzuki and Gychka (2021) wrote, “Thus, these ‘in vivo’ studies demonstrated that the Spike protein of SARS-CoV-2 (without the rest of the virus) reduces the ACE2 expression, increases angiotensin II levels, and exacerbates lung injury.” The ‘in vivo’ studies referred here (Kuba et al., 2005) had shown that SARS coronavirus-induced lung injury was primarily due to the inhibition of ACE2 by the SARS-CoV Spike protein, causing a large increase in angiotensin-II
Suzuki et al (2021) then experimentally demonstrated that the S1 component of the SARS-CoV-2 virus, at a low concentration of 130 pM, activated the MEK/ERK/MAPK signalling pathway to promote cell growth. They hypothesized that these effects would not be limited to the lung vasculature only. The signalling cascade triggered in the vascular system of the heart could cause coronary artery disease, and in the brain, activation could lead to stroke. Systemic hypertension would also be expected.
An interesting study by Lei et. al. (2021) found that pseudovirus — spheres complemented with the SARS-CoV-2 S1 protein but lacking any viral DNA in their nuclei — caused inflammation and damage in both the arteries and lungs of mice exposed intratracheally. They then exposed healthy human endothelial cells to the same pseudovirus particles. Binding of these particles to endothelial ACE2 receptors led to mitochondrial damage and fragmentation in those endothelial cells, leading to the characteristic pathological changes in the associated tissues. This study makes it clear that Spike protein alone, not associated with the rest of the viral genome, is sufficient to cause the endothelial damage associated with COVID-19 disease.
Buzhdygan et al (2020) proposed that primary microvascular endothelial cells in the human brain may cause these symptoms. ACE2 is ubiquitously expressed in endothelial cells of brain capillaries. ACE2 expression is upregulated in people with dementia and hypertension, both of which are risk factors for severe disease from SARS-CoV-2.
In an in vitro study of the blood-brain barrier, the S1 component of Spike protein promoted loss of barrier integrity, suggesting that Spike protein acting alone triggers a pro-inflammatory response in brain endothelial cells, which may explain the neurological consequences of the disease (Buzhdygan et al, 2020).
The implications of this observation are worrisome because mRNA (and the vector-based DNA vaccines as well albeit by a different mechanism) vaccines induce the synthesis of Spike protein, which could theoretically act in a similar way damaging the brain.
The Spike protein generated endogenously by the vaccine could also negatively impact the male testicles, as the ACE2 receptor is highly expressed in testicular Leydig cells (Verma et al., 2020).
Several studies have now shown that the coronavirus Spike protein is able to access testicular cells via the ACE2 receptor, and disrupt male reproduction (Navarra et al., 2020; Wang and Xu, 2020).
A paper on post-mortem examination of the testicles of six male patients with COVID-19 found microscopic evidence of Spike protein in the interstitial cells of the testicles of the patients, testicles which were damaged (Achua et al., 2021).
Puntmann et al. (JAMA Cardiol. 2020;5:1265-1273) showed that a prospective study of 100 recently recovered German COVID-19 patients revealed significant cardiac involvement on cardiac MRI scans in 78% of them, on average 2.5 months after recovery from the acute disease. Two-thirds of these patients were never hospitalized and 60% had ongoing myocardial inflammation. These abnormalities occurred independently of pre-existing conditions, the severity of the initial disease, and the overall course of the acute disease.
Magro et al. showed that there is damage mediated by complement deposition even in grossly normal skin of coronavirus-infected individuals (Human Pathology 2020:106:106-116). They also showed (Magro et al. Annals of Diagnostic Pathology 2021:50 in press) that ACE2 receptor expression is highest in the microvasculature of the brain and subcutaneous fat, and to a lesser degree in the liver, kidneys, and heart.
They also demonstrated that the coronavirus replicates almost exclusively in the endothelial cells of the septal capillaries of the lungs and nasopharynx, and that the viral lysis and the immune destruction of these cells releases viral capsid proteins that travel through the bloodstream and bind to the ACE2 receptors in other parts of the body – resulting in the activation of complement by mannose-binding lectin that not only damages the microvascular endothelium but also induces the production of numerous pro-inflammatory cytokines.
Meinhardt et al. (Nature Neuroscience 2020, in press) show that the Spike protein in the brain endothelial cells is associated with the formation of micro-thrombi (mini blood clots), and like Magro et al. do not find viral RNA in brain endothelium. In other words, viral proteins appear to be causing tissue damage without actively replicating virus.
E.Taglauer describes “Consistent localization of SARS-CoV-2 peak glycoprotein and ACE2 in relation to the predominance of TMPRSS2 in placental villi of 15 COVID-19 positive maternal-fetal dyads.” Parenchymal changes in placentas of COVID-19-infected mothers have been reported by several groups. Could this be associated with the occurrence of miscarriage in vaccinated women?
Ogata et al. write in their paper “Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients” that the Spike protein circulates throughout the body from day 1 after injection and therefore does not remain only at the injection site.
This explains why the neurological symptoms associated with COVID-19, such as headache, nausea and dizziness, encephalitis, and fatal cerebral blood clots, are all indicators of the pathogenic effects of the virus as well as the Spike protein, and it may explain the many side effects seen in vaccinated individuals.
Hansen et al. published the following article in April 2021: First case of postmortem study in a patient vaccinated against SARS-CoV-2. In the “postmortem molecular mapping” viral DNA was identified in almost all organs except the liver and the olfactory bulb.
IV Discussion :
The genetically engineered “vaccines” against Covid-19 (gene vaccines) have profited from extremely early and exceptional marketing authorization conditions. Despite the preliminary results, conveyed in ways by the manufacturers, as to demonstrate their effectiveness, the assertions related to this new technology have, in practice, turned into profoundly troubling concerns for several reasons. One of these, concerns the Spike protein itself, whose manufacture in large quantities in the host cells after introduction of the genetic code seems to be linked to severe and potentially fatal vascular damages. The studies and observations related to this subject bring therefore serious concerns.
While there are still some areas to understand, there is a very strong presumption that the Spike protein, which is the key component of the SARS-CoV-2 vaccine mechanism, is also responsible for damaging organs distant from the injection site, including the brain, heart, lungs, kidneys, and reproductive organs.
As the above presented statistics demonstrates, the vaccines currently in use can trigger potentially fatal short-term adverse effects (more than 10,000 currently in the European Union), some of which most likely being the result of damage to the blood vessels in various organs. Furthermore, while we are not able to know the magnitude of the intermediate let alone surmise the long-term consequences related to, inter alia, the damage to the vascular endothelium, but we can assume that they will be significant.
Before any of these vaccines are officially approved for widespread use in humans in different categories and age groups, it is important to be able to assess more precisely the effects, in vaccinated subjects, of the production of the Spike protein that triggers an immune response.
Based on the celebrated precautionary principle, promoted by all health authorities in handling of the Covid Pandemic, we call for a moratorium to and a re-evaluation of the ongoing vaccination campaign, and await clarification of these serious adverse effects caused by the Spike protein.
Accordingly, with the current information as presented, we cannot allow ourselves to run the risk of finding out later that many healthy people have suffered irreparable iatrogenic damage to their health following these vaccinations, when we actually should suspect them.
V. We urge Public Health Authorities to immediately reconsider the authorization of mass vaccination pending unequivocal clarification of the safety and efficacy of the available SARS-CoV2 vaccines.
Suzuki, 2020 ; Suzuki et al., 2020 ; Suzuki et al., 2021 ; Suzuki et Gychka, 2021.
Kuba et al., 2005
Buzhdygan et al. (2020)
Verma et al., 2020
Navarra et al., 2020 ; Wang et Xu, 2020
Achua et al., 2021
Puntmann et al. (JAMA Cardiol. 2020;5:1265-1273)
Magro et al. (Human Pathology 2020:106:106-116)
Magro et al. Annals of Diagnostic Pathology 2021:50 in press
Meinhardt et al. (Nature Neuroscience 2020, sous presse)
E.Taglauer ” La localisation cohérente de la glycoprotéine de pointe du SARS-CoV-2 et de l’ACE2 par rapport à la prédominance du TMPRSS2 dans les villosités placentaires de 15 dyades materno-fœtales positives au COVID-19 « .